Research programme: cardiovascular disorder therapeutics - InCarda Therapeutics

Drug Profile

Research programme: cardiovascular disorder therapeutics - InCarda Therapeutics

Latest Information Update: 09 Oct 2015

Price : $50

At a glance

  • Originator InCarda Therapeutics
  • Class Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Paroxysmal atrial fibrillation
  • Research Cardiovascular disorders

Most Recent Events

  • 06 Oct 2015 InCarda Therapeutics has patent protection for inhaled cardiovascular therapeutics in Australia, Canada and USA
  • 28 Apr 2015 Early research in Cardiovascular disorders in USA (Inhalation)
  • 28 Apr 2015 Preclinical trials in Paroxysmal atrial fibrillation in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top